Novo Nordisk remains a cautious buy as it faces pressure on adjusted sales and EBIT in Q1 2026 but raised its guidance due to strong uptake of its Wegovy pill. The stock trades at a historically low price-to-earnings ratio of 12.5 times trailing twelve months, indicating market pessimism despite potential growth and multiple expansion after 2026. Competitive risks from Eli Lilly and generics in India and China continue, but Novo Nordisk's higher-dose semaglutide and leading diabetes franchise support its investment appeal. The analyst maintains a Buy rating, seeing an attractive risk-reward balance with expected growth resumption post-2026 reset.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
